Tenax Therapeutics is trading 6.2% higher at $1.44, with no verified October 16 announcement explaining the after-hours rebound. - It closed at $1.36 on October 16 after five consecutive sessions of declines, including a 9.93% drop during regular trading. - The October 8 LEVEL-2 enrollment pause and trial-criteria changes are prior context, not a confirmed catalyst. - Broader markets were sharply lower; available evidence does not establish a clear reason for the after-hours gain.